

CLAIMS

1. A pharmaceutical composition for treating chronic hepatitis C, comprising at least one active ingredient selected from the group consisting of IL-15, myeloid
5 dendritic cell maturation stimulators and lectin-binding substances.
2. The pharmaceutical composition according to Claim 1, comprising IL-15.
3. The pharmaceutical composition according to Claim 2 for use together with IFN-a in treatment of chronic hepatitis C, comprising IL-15.
4. The pharmaceutical composition according to Claim 1, comprising a myeloid
10 dendritic cell maturation stimulator.
5. The pharmaceutical composition according to Claim 4 for use together with IFN-a in treatment of chronic hepatitis C, comprising a myeloid dendritic cell maturation stimulator.
6. The pharmaceutical composition according to Claim 4 or 5, wherein the
15 myeloid dendritic cell maturation stimulator is selected from the group consisting of CpG oligo deoxynucleotide, GM-CSF, IL-4, LPS, CD40L, polyI:C, TNF-a and IFN-?.
7. The pharmaceutical composition according to Claim 1, comprising a lectin-binding substance.
8. The pharmaceutical composition according to Claim 7 for use together with
20 IFN-a in treatment of chronic hepatitis C, comprising a lectin-binding substance.
9. The pharmaceutical composition according to Claim 7 or 8, wherein the lectin-binding substance is selected from the group consisting of mannose carbohydrates, fucose carbohydrates and anti-lectin antibodies.
10. A pharmaceutical composition for preventing hepatic cirrhosis or hepatic cell
25 carcinoma, comprising at least one active ingredient selected from the group consisting of IL-15, myeloid dendritic cell maturation stimulators and lectin-binding substances.
11. A method of treating chronic hepatitis C, comprising administration to a patient of an effective amount of at least one active ingredient selected from the group consisting of IL-15, myeloid dendritic cell maturation stimulators and lectin-binding
30 substances.
12. Use of IL-15, myeloid dendritic cell maturation stimulator and/or lectin-binding substance in manufacture of a medicine for treatment of chronic hepatitis C.